BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO John Oyler Sells 1,460 Shares

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 1,460 shares of the firm's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $256.49, for a total value of $374,475.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

John Oyler also recently made the following trade(s):

• On Monday, June 16th, John Oyler sold 3,680 shares of BeOne Medicines stock. The stock was sold at an average price of $266.05, for a total transaction of $979,064.00.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The stock was sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Trading Down 2.3%

NASDAQ:ONC traded down $5.70 during trading hours on Friday, reaching $247.08. The company had a trading volume of 230,772 shares, compared to its average volume of 298,435. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96. BeOne Medicines Ltd. - Sponsored ADR has a 52 week low of $141.31 and a 52 week high of $287.88. The stock has a market cap of $27.07 billion, a price-to-earnings ratio of -66.42 and a beta of 0.30. The company's 50 day simple moving average is $245.59.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of ($0.71) by $1.93. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. On average, analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ONC shares. Bank of America upgraded shares of BeOne Medicines from a "neutral" rating to a "buy" rating and raised their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Guggenheim raised their price target on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. TD Securities reissued a "buy" rating and set a $334.00 price target on shares of BeOne Medicines in a research report on Thursday, April 24th. Sanford C. Bernstein set a $259.00 target price on BeOne Medicines in a report on Thursday, March 13th. Finally, JMP Securities set a $348.00 target price on BeOne Medicines in a report on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.